Micro-cap and clinical-stage biotechnology stocks like Enveric Biosciences frequently experience sharp share price declines due to factors such as public equity offerings, dilution from warrant exercises, clinical trial delays, regulatory hurdles, or broader macroeconomic volatility affecting the biotechnology sector. Investors monitoring such equities typically review official corporate SEC filings and financial disclosures to identify the specific catalysts behind individual stock price drops.